Oxford, UK: 6 July 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has signed a license agreement with Children’s Hospital Boston to extend the Company’s existing rights for the anti-angiogenic genes, endostatin and angiostatin, for the treatment of cancer using gene therapy. Angiogenesis, which is the formation of new blood vessels, is a critical mechanism for tumour progression. It has been clinically proven that tumour growth can be suppressed by using anti-angiogenic approaches to inhibit tumour angiogenesis. Endostatin and angiostatin are endogenous anti-angiogenic proteins discovered in the laboratory of Dr. Judah Folkman, director of the Vascular Biology Program at Children’s Hospital Boston.
